Transcranial Magnetic Stimulation for Depression

San Jose, CA

N/A

Waitlist Available

Research Sponsored by NeuroQore Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Males or females aged 22-85

Current diagnosis of major depressive disorder according to the criteria defined in the current Diagnosis and Statistical Manual of Mental Disorders (DSM-V) without psychotic features

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from enrollment to final madrs score assessment within 2 weeks.

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to test a new way of using Transcranial Magnetic Stimulation (TMS) therapy to treat Major Depressive Disorder. Instead of the traditional 5 days per week for 6

See full description

Who is the study for?

Adults aged 22-85 with Major Depressive Disorder (MDD) can participate in this trial. The study is testing a new, accelerated TMS treatment schedule to see if it's as safe and effective as the standard regimen.Check my eligibility

What is being tested?

The trial is studying an accelerated version of Transcranial Magnetic Stimulation (TMS) therapy for MDD. Instead of daily sessions over six weeks, participants receive three 19-minute sessions in one day.See study design

What are the potential side effects?

TMS may cause discomfort at the treatment site, headache, lightheadedness, or seizures in rare cases. Most side effects are mild and improve shortly after each session.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 22 and 85 years old.

show original

Select...

I have been diagnosed with major depression without experiencing psychosis.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from enrollment to final phq-9 score assessment within 2 weeks.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from enrollment to final phq-9 score assessment within 2 weeks.

This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to final phq-9 score assessment within 2 weeks. for reporting.